Elanco Animal Health (NYSE:ELAN) Releases Q4 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its fourth quarter 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.090-0.120 for the period, compared to the consensus EPS estimate of 0.140. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Elanco Animal Health also updated its FY 2025 guidance to 0.910-0.940 EPS.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN traded down $0.43 during trading on Wednesday, hitting $22.08. 6,858,305 shares of the company traded hands, compared to its average volume of 5,896,664. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. The business’s fifty day moving average is $19.98 and its 200-day moving average is $16.00. The stock has a market capitalization of $10.97 billion, a price-to-earnings ratio of 25.72, a PEG ratio of 3.56 and a beta of 1.71. Elanco Animal Health has a one year low of $8.02 and a one year high of $22.98.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the firm earned $0.13 EPS. The company’s quarterly revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. As a group, equities analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on ELAN. JPMorgan Chase & Co. raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. Leerink Partnrs upgraded shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 17th. Piper Sandler upped their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, August 11th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Elanco Animal Health in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus raised their price target on shares of Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $20.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geneos Wealth Management Inc. grew its position in shares of Elanco Animal Health by 53.7% during the 2nd quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock worth $85,000 after purchasing an additional 2,080 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Elanco Animal Health by 26.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock worth $91,000 after acquiring an additional 1,332 shares during the period. Cresset Asset Management LLC raised its stake in shares of Elanco Animal Health by 12.8% during the second quarter. Cresset Asset Management LLC now owns 11,338 shares of the company’s stock valued at $162,000 after acquiring an additional 1,287 shares during the last quarter. Empowered Funds LLC raised its stake in shares of Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after acquiring an additional 4,121 shares during the last quarter. Finally, Vident Advisory LLC raised its stake in shares of Elanco Animal Health by 14.5% during the second quarter. Vident Advisory LLC now owns 16,952 shares of the company’s stock valued at $242,000 after acquiring an additional 2,144 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.